secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2026-05-27T20:15:26+00:00
Accession:  0001104659-26-066956
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio terminates Gemma collaboration and exits Philadelphia office lease with $2.3M fee
--------------------------------------------------------------------------------

- Terminated Gemma Biotherapeutics collaboration covering Huntington's disease and Temporal Lobe Epilepsy programs, effective May 21, 2026.
- Termination also eliminates options for four new CNS indications under the July 2024 agreement.
- Paid $2.3M to exit 37,000 sq ft office lease (originally expiring Dec 2031); company is remote-only.
- Subleases previously covered substantially all of that office space.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000110465926066956/0001104659-26-066956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000110465926066956/pasg-20260521x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-066956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer